NovoCure Limited - Ordinary Shares (NVCR)

If you have decades of investing runway left, consider these two top healthcare stocks.

Novocure (NVCR) beat Q3 2025 revenue estimates and narrowed its loss, with shares rising. The oncology firm is expanding its Tumor Treating Fields therapy into new cancers.

Investment bank analysts up and down Wall Street are pounding the table on these stocks.

TTField therapy with chemotherapy improved median overall and pain-free survival in pancreatic cancer, according to new data from the PANOVA-3 trial.

NovoCure posted a smaller-than-expected Q1 loss with 12% revenue growth, while monitoring tariff shifts that could impact 2025 costs.

NovoCure posted stronger-than-expected Q1 2025 results, driven by revenue and GAAP earnings surpassing estimates.

NVCR earnings call for the period ending December 31, 2024.